跳至主要内容
临床试验/IRCT20220111053692N5
IRCT20220111053692N5招募中未知

Bioequivalence study of Gabapentin 300 mg Capsule (Teb Mofid Nikan) versus Neurontin 300 mg (Pfizer) Capsule after single oral dosing in healthy volunteers

Teb Mofid Nikan Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 55 years(—)
性别
Male

入选标准

  • 18 to 55 years old
  • Weight in range of 10 % proper body weight
  • All volunteers should be in a good health condition on the basis of medical history, physical examination, routine blood test.
  • and possessing negative test for hepatitis B surface antigen (HBs-Ag), antihepatitis-C antibody (anti-HCV), and anti-HIV.

排除标准

  • Volunteers with hypersensitivity to Gabapentin were excluded.
  • those with known history of drug abuse. alcohol consumer or cigarette smokers.
  • Taking medications that have drug interactions with Gabapentin until one month before studying.
  • disinclination to take the test
  • Blood donation or blood loss of more than 200 ml in the past month

研究者

发起方
Teb Mofid Nikan Pharmaceutical Company

相似试验